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Abstract
OBJECTIVE: To investigate the protective role of Si-
junzi decoction in neuromuscular junction (NMJ)
and muscle cell mitochondria ultrastructure; as
well as its effects on the amount of adenosine tri-
phosphate (ATP) and the activities of mitochondrial
respiratory chain complexes I, II, III, and IV in auto-
immune myasthenia gravis rats.
METHODS: An experimental autoimmune myas-
thenia gravis (EAMG) rat model was established
by inoculating rats with acetylcholine receptors
extracted from Torpedo. Rats were divided into
three groups: model, prednisone, and Sijunzi de-
coction, and were fed physiological saline, predni-
sone, or Sijunzi decoction, respectively. NMJ and
muscle cell mitochondria ultrastructure were ob-
served by transmission electron microscope. The
amount of ATP was assessed by high perfor-
mance liquid chromatography. The activities of
mitochondrial respiratory chain complexes I, II, III,
and IV was determined using the Clark oxygen
electrode method.
RESULTS: In the model group, there were sparse
muscle fibers, with decreased mitochondria, and
sparse, diffluent, or absent NMJ folds. After inter-
vention with Sijunzi decoction, the above patholo-
gy changes were improved: muscle fiber structure
was clear and complete; the mitochondria count
was higher; and the NMJ structure was close to nor-
mal. Gastrocnemius muscle mitochondria in the
model group produced significantly less ATP than
those in the prednisone group (P<0.01). Converse-
ly, the ATP of Sijunzi decoction group was signifi-
cantly higher than prednisone group (P<0.01). The
activities of gastrocnemius muscle mitochondrial
respiratory chain complexes I, II, III, and IV in both
the prednisone and Sijunzi decoction groups was
dramatically higher compared with the model
group (P<0.05). The activities of complexes I and III
in the Sijunzi decoction group were significantly
higher than those in the prednisone group (P<
0.05), but there was no obvious difference in com-
plex II or IV activities between the two groups (P>
0.05).
CONCLUSION: Sijunzi decoction improved patho-
logical changes in muscle mitochondria and NMJ,
enhanced the amount of ATP in gastrocnemius
muscle mitochondria, and improved the activities
of respiratory chain complexes I, II, III, and IV (espe-
cially I and III) of the EAMG rats.
© 2013 JTCM. All rights reserved.
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INTRODUCTION
Myasthenia gravis (MG) is an autoimmune-mediated
disorder of the neuromuscular junction (NMJ).1 Clini-
cally, MG is characterized by painless and fluctuating
weakness of striated muscles.2 Anti-acetylcholine recep-
tor antibody (AChR-Ab) is the main cause of the dis-
ease,3 but in some patients AChR-Ab cannot be detect-
ed.4 Mitochondrial abnormalities can lead to muscle
cell damage that may also result in MG.5 Liu et al 6,7
put forward the spleen-mitochondrial related theory,
and confirmed reinforcing Qi strengthening spleen for-
mula Sijunzi decoction played a protective role in gas-
tric mucosa cell mitochondria. Mitochondrial aerobic
oxidation energy is derived mainly from the respiratory
chain,8 and the activities of its resident enzymes play es-
sential roles in maintaining mitochondrial structure
and function and adenosine triphosphate (ATP) pro-
duction.9 According to theories of spleen governing
transformation and transportation and the spleen-mito-
chondrial relation, we have confirmed that a therapy of
reinforcing Qi strengthening spleen can protect muscle
mitochondria.16 Based on the studies above, this study
investigated the protective effect of Sijunzi decoction
on the NMJ ultrastructure, ATP content in gastrocne-
mius muscle mitochondria, and the activities of mito-
chondrial respiratory chain complexes Ⅰ, Ⅱ, Ⅲ, andⅣ in experimental autoimmune myasthenia gravis
(EAMG) rats.
MATERIALS ANDMETHODS
Time and setting
Neuropathophysiological, randomized, controlled ex-
periment, conducted at the Laboratory of Internal
Medicine of First Affiliated Hospital and the Laborato-
ry of Basic Medical Science of Guangzhou University
of Traditional Chinese Medicine between December
2010 and October 2011.
Animals
A total of 45 female Lewis rats 2 months of age weigh-
ing 155±16 g were purchased from the Animal Center
of Health Science Base of Peking University [license
No. SYXK (Jing) 2010-2011]. The experimental ani-
mals were sacrificed according to Guidance Sugges-
tions for the Care and Use of Laboratory Animals pub-
lished by the Ministry of Science and Technology of
the People's Republic of China in 2006.10 The experi-
mental procedures were approved by the Research Eth-
ics Committee of Guangzhou University of TCM,
China.
Drugs
Sijunzi decoction: Renshen (Radix Ginseng) 9 g, Fuling
(Poria) 9 g, Cangzhu (Rhizoma Atractylodis Lanceae)
9 g, Gancao (Radix Glycyrrhizae) 6 g (Xingyuanchun
pharmacy, Guangzhou, China). The concentration of
Sijunzi decoction was 160 g/L. Prednisone was pur-
chased from Guangzhou Pharmaceutical Holdings Ltd,
China (batch No. 20080121073).
Model establishment
EAMG rat model was established using acetylcholine
receptors extracted from Torpedo as detailed else-
where.11,12 Briefly, AchRs were purified from electric or-
gan extracts using immune affinity chromatography
and emulsified in Complete Freund's Adjuvant (CFA)
(BD Biosciences). To model EAMG 45 rats were im-
munized once by injection of purified AChR (30 bg/
rat) in the base of the tail. We then observed the immu-
nized rats daily performance, and recorded food intake,
body weight, and symptoms according to Lennon's
method.13 The presence of AchR-Abs in serum from
the EAMG model rats was confirmed by Eliza.14
Grouping and intervention
Thirty successfully established EAMG model rats were
randomly divided into three groups according to the
random number table, 10 rats in each. After one week,
the appropriate treatment was administered to each
group by lavage once daily as follows: model group:
physiological saline 10 mL/kg-1·d-1; prednisone group:
prednisone at a dose of 5.4 mg/kg-1·d-1; Sijunzi decoc-
tion group: Sijunzi decoction 37.6 g/kg-1·d-1.
Ultrastructural analysis
After 12 h fasting, all rats were killed by decapitation.
The tibia anterior muscle branch along the sciatic
nerve was dissected, cut into 1-2 mm3 pieces, fixed in
2.5% glutaraldehyde, and viewed by an electron micro-
scope (H-600, Hitachi, Ltd., Japan). The gastrocne-
mius was cut into three blocks (weighing up to about 1 g
each). Mitochondria were extracted from the blocks via
centrifugation and ATP was measured using high per-
formance liquid chromatography.15
Measurement of mitochondrial respiratory chain
complex enzyme activities
Gastrocnemius mitochondria were separated according
to Kesavulu.16 Mitochondrial respiratory chain enzy-
matic activities of complexes Ⅰ, Ⅱ, Ⅲ, and Ⅳ was
measured using the Clark oxygen electrodes method.17
Statistical analysis
Order parameter S data were expressed as the mean ±
standard deviation (SD) and processed using SPSS
11.0 software (SPSS, Chicago, IL, USA). Statistical
analysis was performed by independent sample t-test
and Pearson correlation analysis. A value of P<0.05 rep-
resented statistical significance.
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RESULTS
Electron microscopy of mitochondria and muscle
fibers
In the model group, the muscle fibers were sparse and
in disorder, with few mitochondria. In the prednisone
group, mitochondrial structure was disordered, with
fine fractures and mitochondrial vacuolation, but mus-
cle fibers were still clear. In the Sijunzi decoction
group, muscle fiber structure was clear and complete,
and the mitochondria count was higher (Figure 1).
Electron microscope observation of the NMJ
In the model group, the NMJ folds were disorganized
and incomplete, with fewer presynaptic vesicles and
vacuolated mitochondria. In the prednisone group, the
NMJ folds were also disordered and incomplete. In the
Sijunzi decoction group, the NMJ was close to normal,
with only a few vacuolated mitochondria (Figure 2).
ATP content of Gastrocnemius muscle mitochondria
Gastrocnemius muscle mitochondrial ATP content in
prednisone and Sijunzi decoction groups were higher
than model group (t=3.52, 12.81, P<0.01). In the Si-
junzi decoction group, ATP content was significantly
higher than that in the prednisone group (t=11.28, P<
0.01) (Table 1).
Activity of mitochondrial respiratory chain
complexesⅠ,Ⅱ,Ⅲ, andⅣ
The activities of gastrocnemius muscle mitochondrial
respiratory chain complexes Ⅰ, Ⅱ, Ⅲ, and Ⅳ in
both the prednisone group and Sijunzi decoction
group was dramatically elevated compared with the
model group after drug intervention (both P<0.05).
The activities of complexes Ⅰ and Ⅲ in the Sijunzi
decoction group was obviously higher than those in
the prednisone group (t=2.77, 4.24, P<0.05), but
there was no obvious difference in the activities of
complexes II and IV between the two groups (t=
0.13, 0.18, P>0.05) (Table 2).
Figure 1 Mitochondria (M) and muscle fiber in three groups under electron microscope
Model group treated with physiological saline (10mL/kg-1·d-1); prednisone group treated with prednisone (5.4 mg/kg-1·d-1); Sijunzi
decoction group treated with Sijunzi decoction (37.6 g/kg-1·d-1). A: model group (×4000); B: prednisone group (×10 000); C: Sijunzi
decoction group (×4000).
A B C
Figure 2 Electron microscopy showing the neuromuscular junction (NMJ) of the three groups
Model group treated with physiological saline (10mL/kg-1·d-1); prednisone group treated with prednisone (5.4 mg/kg-1·d-1); Sijunzi
decoction group treated with Sijunzi decoction (37.6 g/kg-1·d-1). A: Model group (×10 000); B: Prednisone group (×8000); C: Sijunzi
decoction group (×6000).
A B C
Group
Model group
Prednisone group
Sijunzi decoction group
n
10
10
10
ATP content
3.5±1.5
5.6±1.1
13.9±2.1
Table 1 ATP content of Gastrocnemius muscle mitochondria
in three groups (nmol/mg, xˉ ±s)
Notes: model group treated with physiological saline (10 mL/
kg-1·d-1); prednisone group treated with prednisone (5.4 mg/
kg-1·d-1); Sijunzi decoction group treated with Sijunzi decoc-
tion (37.6 g/kg-1·d-1). Data were expressed as mean±SD. Statisti-
cal analysis was performed by independent sample t-test. The ex-
periment was repeated three times.
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DISCUSSION
MG is an autoimmune disease that affects the AchRs
of the postsynaptic membrane of the neuromuscular
junctional cleft, through a mechanism that is acetylcho-
line receptor antibody mediated and involves cell de-
pendent immunity and the complement pathway.18
The basic pathogenesis of MG is the production of
AchR-Ab, resulting from the response of autoreactive T
lymphocytes to AChR. AchR-Ab can be detected in
about 80%-90% of general type MG patients.19 Some
scholars pointed out that the AchR-Ab of EAMG rats
and humans were the same immune globulin, and
could inhibit the activities of N-AchR.20-24 However,
Romi et al 25 found the titer of AchR-Ab and the severi-
ty of clinical symptoms are not correlated. AchR-Ab
could not be detected in a few patients with clinical fea-
tures of myasthenia gravis, indicating that other anti-
bodies may participate in the disease.26 Therapy based
on improving NMJ transfer and inhibition of autoim-
mune reaction is effective, but toxic effects and adverse
reactions are obvious,27,28 especially after muscle cell
damage, which often fails to improve.
MG patients have facial and medulla oblongata muscle
weakness and muscle atrophy, which suggest the patho-
genesis of MG is the result of the interaction of many
factors.29,30 Dysfunction between acetylcholine motor
neurons and skeletal muscle is the main pathogenesis.
Moreover, mitochondrial damage causes muscle cell
damage resulting in MG.6 Intracellular oxidative phos-
phorylation and ATP form in the mitochondria, also
called the "power factory". If the mitochondria count
in muscle tissue decreased or mitochondria dysfunc-
tion occurred, insufficient energy to maintain muscle
contraction muscle would result in muscle weakness.9
According to "spleen rules transformation and trans-
portation," Liu6 put forward the spleen- mitochondrial
related theory in 1987. He thought the explanation of
"spleen governing transformation and transportation"
referred not only to the food during gastrointestinal di-
gestion and absorption, but the mitochondrial biologi-
cal oxidation process as well. In 1991, Liu et al 6,7 con-
firmed reinforcing Qi strengthening spleen formula Si-
junzi decoction played a protective role in mitochon-
dria of gastric mucosa cells in Kyoto University. Our
further study found Sijunzi decoction repaired dam-
aged COX subgenes coded by mtDNA induced by
spleen asthenia as well as elevate the amount of cyto-
chrome and its oxidation activities.31 Furthermore, Si-
junzi decoction improved the general condition of
EAMG rats including their symptoms, and the color
and luster of their fur. It also improved the expression
of 8-oxoguanine DNA glycosylase 1, thymine glycol
DNA glycosylase, 3-methylpurine DNA glycosylase
and the amount of ATP in muscle mitochondria.15 In
this study, we find Sijunzi decoction repaired pathologi-
cal changes of the NMJ, increased the mitochondria
count, and improved the activities of mitochondrial re-
spiratory chain complexes Ⅰ, Ⅱ, Ⅲ, and Ⅳ, especial-
ly Ⅰ and Ⅲ. Sijunzi decoction enhanced the amount
of muscle mitochondrial ATP by protecting the mito-
chondria count and improving the activities of mito-
chondrial respiratory chain complexes Ⅰ and Ⅲ.
Bloeh et al32 found that energy metabolism inhibitor
could cause impaired mitochondria function in both
pre- and post-synaptic cells, which resulted in neuro-
muscular transmission disorder by reducing presynap-
tic acetylcholine production and the amount of post-
synaptic AchR. Finsterer et al 33 found that disrupting
the mitochondrial respiratory chain complex caused re-
spiratory chain disorders that were very similar with
the ocular type of MG. Our results are consistent with
these observations.
In conclusion, Sijunzi decoction repaired damaged gas-
trocnemius mitochondria and NMJ ultrastructure in
EAMG rats. We speculate that Sijunzi decoction im-
proves mitochondrial respiratory chain enzyme activi-
ties and mitochondrial ATP content to achieve this
function.
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